Form 4: GeneDx Holdings CEO Katherine Stueland Reports RSU Vesting and Tax-Related Stock Sale

GeneDx Holdings Corp.'s CEO and Director, Katherine Stueland, reported the vesting of 18,750 restricted stock units and a subsequent sale of 10,501 shares to cover tax withholding obligations.

Summary

• Katherine Stueland, Chief Executive Officer and Director of GeneDx Holdings Corp. (WGS), reported transactions on June 16, 2025, as detailed in a Form 4 filing.
• She acquired 18,750 shares of Class A Common Stock through the vesting of Restricted Stock Units (RSUs) at a price of $0 per share.
• Concurrently, Ms. Stueland sold 10,501 shares of Class A Common Stock at a price of $64.773 per share.
• This sale was explicitly stated to be a "sell to cover" transaction, intended solely to satisfy tax withholding obligations in connection with the RSU vesting, and was not a discretionary transaction.
• Following these transactions, Ms. Stueland directly owns 14,597 shares of Class A Common Stock and 131,250 Restricted Stock Units.
• Each RSU represents a contingent right to receive one share of Class A Common Stock for no consideration.
• The RSUs vest at a rate of 6.25% in quarterly installments over a four-year period, commencing March 16, 2023, contingent on her continued service to the Issuer.

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation event (RSU vesting) and a non-discretionary sale to cover tax obligations. This is a neutral to slightly positive event as it indicates continued executive tenure and a standard compensation process, with no negative discretionary selling.

Positives

• The vesting of Restricted Stock Units indicates the fulfillment of compensation agreements for the CEO, reflecting her continued service and commitment to the company.
• The "sell to cover" transaction is a standard and non-discretionary practice for executives to manage tax liabilities upon RSU vesting, and does not signal a lack of confidence in the company's future.

Negatives

• The sale of 10,501 shares, even for tax purposes, results in a reduction of the CEO's direct equity ownership in the company's Class A Common Stock.

Future Outlook

This Form 4 filing, which reports insider transactions related to executive compensation, does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• "The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs."
• "The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person."

Industry Context

This filing details a routine executive compensation event for a publicly traded company. It does not provide specific industry-wide context beyond illustrating a common method of equity-based compensation and tax management for executives in the public markets.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a widespread practice across various industries, including biotechnology and healthcare, serving to align executive incentives with long-term shareholder value.
• The "sell to cover" mechanism for tax withholding upon RSU vesting is a standard and widely accepted practice for executives in publicly traded companies, ensuring compliance with tax obligations without requiring personal funds and is not indicative of a discretionary sale based on market sentiment.

Stakeholder Impact

• Shareholders: The transactions are routine and expected for executive equity compensation. The "sell to cover" sale is not indicative of a change in management's confidence, and the continued RSU holdings align executive incentives with long-term shareholder value.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Continued quarterly vesting of the remaining 131,250 Restricted Stock Units over the 4-year period commencing March 16, 2023, subject to Katherine Stueland's continued service to GeneDx Holdings Corp.

Key Dates

Recommendation

Keywords

GeneDx Holdings Corp., WGS, SEC Form 4, Insider Trading, Katherine Stueland, CEO, Director, Restricted Stock Units, RSU Vesting, Stock Sale, Sell to Cover, Executive Compensation, Beneficial Ownership